Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Lilly is still worth over $500 billion, but its market capitalisation has shed almost a third in the past year. With ...

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

A late-stage trial shows a daily pill helped people lose 12% of their body weight—without injections. Nine teens arrested ...

Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September ...

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...